CYTOO is a preclinical stage drug discovery company specialized in muscular and neuromuscular disorders. CYTOO partners its versatile patient-derived muscle drug discovery engine to pharma and biotech companies and develops its own drug candidates. CYOO has developed a fully mature human in vitro muscle model (MyoScreen) derived from primary human samples (healthy and pathological myoblasts) for generating NCEs from a variety of pathological conditions (rare, chronic). Core expertise lies on in vitro muscle regeneration, contraction, hypertrophy, and metabolism.
Looking for a particular CYTOO employee's phone or email?
The CYTOO annual revenue was $1 million in 2026.
Marc Liberatore is the CEO of CYTOO.
20 people are employed at CYTOO.
The NAICS codes for CYTOO are [5417, 541713, 541, 54, 54171].
The SIC codes for CYTOO are [87, 873].